Syros Pharmaceuticals, Inc. financial data

Location
Cambridge, MA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2024 - 31 Oct 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 320% % -46%
Return On Equity -2747% % -2151%
Return On Assets -79% % -47%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 26,832,457 shares
Common Stock, Shares, Outstanding 26,832,457 shares 29%
Common Stock, Value, Issued $27,000 USD 29%
Weighted Average Number of Shares Outstanding, Basic 39,335,772 shares 41%
Weighted Average Number of Shares Outstanding, Diluted 39,335,772 shares 41%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $88,639,000 USD -23%
General and Administrative Expense $23,272,000 USD -22%
Operating Income (Loss) $111,659,000 USD 19%
Net Income (Loss) Attributable to Parent $97,815,000 USD 6.8%
Earnings Per Share, Basic -3 USD/shares -301%
Earnings Per Share, Diluted -3 USD/shares -301%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $58,275,000 USD -48%
Marketable Securities, Current $24,781,000 USD -59%
Cash, Cash Equivalents, and Short-term Investments $108,300,000 USD
Assets, Current $63,931,000 USD -48%
Property, Plant and Equipment, Net $6,308,000 USD -17%
Operating Lease, Right-of-Use Asset $11,271,000 USD -9.6%
Other Assets, Noncurrent $1,366,000 USD -35%
Assets $84,995,000 USD -42%
Accounts Payable, Current $9,646,000 USD 238%
Employee-related Liabilities, Current $4,788,000 USD -40%
Liabilities, Current $28,392,000 USD -0.01%
Operating Lease, Liability, Noncurrent $16,561,000 USD -13%
Retained Earnings (Accumulated Deficit) $756,238,000 USD -15%
Stockholders' Equity Attributable to Parent $11,123,000 USD -131%
Liabilities and Equity $84,995,000 USD -42%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $31,098,000 USD 16%
Net Cash Provided by (Used in) Financing Activities $265,000 USD
Net Cash Provided by (Used in) Investing Activities $24,640,000 USD 4.3%
Common Stock, Shares Authorized 140,000,000 shares 100%
Common Stock, Shares, Issued 26,832,457 shares 29%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $56,003,000 USD 11%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $60,394,000 USD -48%
Interest Paid, Excluding Capitalized Interest, Operating Activities $1,209,000 USD 15%
Operating Lease, Liability $20,296,000 USD -9.3%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $97,815,000 USD 6.6%
Lessee, Operating Lease, Liability, to be Paid $26,673,000 USD -13%
Operating Lease, Liability, Current $2,584,000 USD 15%
Lessee, Operating Lease, Liability, to be Paid, Year Two $4,412,000 USD 2.9%
Lessee, Operating Lease, Liability, to be Paid, Year One $4,287,000 USD 2.9%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $6,377,000 USD -24%
Lessee, Operating Lease, Liability, to be Paid, Year Three $4,541,000 USD 2.9%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Operating Lease, Payments $1,037,000 USD 3%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization $334,000 USD -48%
Share-based Payment Arrangement, Expense $7,251,000 USD -38%
Interest Expense $5,321,000 USD 14%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%